

Clinical Trial Protocol

Iranian Registry of Clinical Trials

06 Jul 2026

Effect of intravaginal application of magnesium sulfate on the intensity of labor pain, and the duration of the first and second stages of labor in nulliparous women referred to Al-zahra hospital: A Clinical Trial

Protocol summary

Study aim

Effect of intravaginal application of magnesium sulfate on the intensity of labor pain, and the duration of the first and second stages of labor in nulliparous women referred to Al-zahra hospital: A Clinical Trial

Design

Clinical trial with control group, with parallel groups, double blind, randomized

Settings and conduct

Location: Guilan university of medical sciences, Al-Zahra hospital, gynecology clinic. 72 eligible patients will be included in this study.

Participants/Inclusion and exclusion criteria

Inclusion criterias: Nullipara women in the active phase of labor ,not being prom ,not using calcium blocker drugs ,woman between age 18-35, prime para, single tone cephalic fetus ,estimated fetal weight between 2500-4000 gr, low risk pregnancy .BMI 19.8-30,no drug abuse. Exclusion criterias: Infertility history, history of dangerous underlying disease,History of drug use during pregnancy, Polyhydramnios, Participate in childbirth preparation classes during pregnancy and the presence of any contraindications to natural childbirth.

Intervention groups

Intervention group: group A, after vaginal examination 10cc of magnesium sulfate 50% will be applied intravaginally on the cervix at the dilatations of 5-6cm,7-8cm 9-10 cm .group B will receive placebo (in the same size and shape) in the same way as group A.

Main outcome variables

Factors examined include intensity of pain in dilatation of 3-5 cm 7-8 cm 09-10 cm of cervix

General information

Reason for update

Acronym

magnesium sulfate

IRCT registration information

IRCT registration number: **IRCT20200510047377N1**

Registration date: **2020-06-18, 1399/03/29**

Registration timing: **prospective**

Last update: **2020-06-18, 1399/03/29**

Update count: **0**

Registration date

2020-06-18, 1399/03/29

Registrant information

Name

Fereshteh Fakoor

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 13 3336 9224

Email address

fereshtehfakor@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-06-24, 1399/04/04

Expected recruitment end date

2021-01-23, 1399/11/04

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of intravaginal application of magnesium sulfate

on the intensity of labor pain, and the duration of the first and second stages of labor in nulliparous women referred to Al-zahra hospital: A Clinical Trial

Public title

Effect of intravaginal application of magnesium sulfate on the intensity of labor pain, and the duration of the first and second stages of labor in nulliparous women referred to Al-zahra hospital

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Nullipara women in the active phase of labor Not being PROM Woman between age 18-35, Prime para Single tone cephalic fetus Estimated fetal weight between 2500-4000 gr Low risk pregnancy BMI 19.8 - 30 Not using calcium blocker drugs No drug abuse Pregnancy age 37 to 42 weeks

Exclusion criteria:

Infertility history History of dangerous underlying disease History of drug use during pregnancy Polyhydramnios Participate in childbirth preparation classes during pregnancy The presence of any contraindications to natural childbirth

Age

From **18 years** old to **35 years** old

Gender

Female

Phase

3

Groups that have been masked

- Participant
- Outcome assessor

Sample size

Target sample size: **72**

Randomization (investigator's opinion)

Randomized

Randomization description

Initially, patients receive a written consent form and execution methods and interventions are explained. Then eligible people, They are randomly assigned to two groups by the method of 4 random blocks. These patients are divided into two groups treated with magnesium sulfate the control group. None of the participants in the study will be notified of the randomization list .for concealment practices we use sealed envelopes that are numbered in order And the envelope for each person only after Confirmation of the eligibility criteria for her to enter the study and Signing the consent ,will be opened. Register and randomization will be done by third person.

Blinding (investigator's opinion)

Double blinded

Blinding description

After generating the list, each person is assigned a unique code and during the study the person will be identified with this code. None of the participants in the study will be aware of the randomization list and also to apply allocation concealment randomization, the groups are placed in closed envelopes in the admission section and eligible individuals who enter the study are included

respectively. Therefore, the study was double-blind so that patients and outcome evaluation specialist are unaware of the allocation status of the two groups to the study.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Guilan University of Medical Sciences

Street address

Research vice-chancellorship Building, in front of 17-Shahrivar Hospital, Shahid Siadati St., Namjoo Ave., Rasht, Guilan, IRAN

City

Rasht

Province

Guilan

Postal code

41446-66949

Approval date

2020-05-27, 1399/03/07

Ethics committee reference number

IR.GUMS.REC.1399.087

Health conditions studied

1

Description of health condition studied

labor facilitation

ICD-10 code

O00-O99

ICD-10 code description

ICD-10 Pregnancy, childbirth and the puerperium

Primary outcomes

1

Description

The intensity of pain in dilatation is 3-5 cm

Timepoint

The time interval between entering the labor and reaching the dilatation 3-5 cm of the cervix

Method of measurement

visual analogue scale

Secondary outcomes

1

Description

The intensity of pain in dilatation is 3-5 cm

Timepoint

The time interval between entering the labor and reaching the dilatation 3-5 cm of the cervix

Method of measurement

visual analogue scale

2

Description

The intensity of pain in dilatation is 7-8 cm

Timepoint

time interval 3-5 until the examination of the cervix 7-8 cm

Method of measurement

visual analogue scale

3

Description

The intensity of pain in dilatation is 9-10 cm

Timepoint

time interval 7-8 until the examination of the cervix 9-10 cm

Method of measurement

visual analogue scale

Intervention groups

1

Description

Intervention group: group A, after vaginal examination 10cc of magnesium sulfate 50% will be applied intravaginal on the cervix at the dilatations of 5-6cm,7-8cm 9-10 cm .

Category

Treatment - Drugs

2

Description

Control group: group B will receive normal saline (in the same size and shape) in the same way as group A.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Al-Zahra hospital

Full name of responsible person

Dr.Fereshteh Fakoor

Street address

Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN

City

Rasht

Province

Guilan

Postal code

41446-66949

Phone

+98 13 3336 9224

Email

fereshtehfakor@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Rasht University of Medical Sciences

Full name of responsible person

Fatemeh Gholamalipour

Street address

Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN

City

Rasht

Province

Guilan

Postal code

54839- 41446

Phone

+98 13 3336 9224

Email

Fatemeh.gholamalipour@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Rasht University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Rasht University of Medical Sciences

Full name of responsible person

Fatemeh Gholamalipour

Position

Resident of gynecologist Professor

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN

City

Rasht

Province

Guilan

Postal code

54839- 41446

Phone

+98 13 3336 9224

Email

Fatemeh.gholamalipour@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Rasht University of Medical Sciences

Full name of responsible person

Dr.fereshteh fakoor

Position

Professor

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN

City

Rasht

Province

Guilan

Postal code

54839 -41446

Phone

+98 13 3336 9224

Email

fereshtehfakor@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Rasht University of Medical Sciences

Full name of responsible person

Seyedeh Maryam Attari

Position

MS of midwifery

Latest degree

Master

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN

City

Rasht

Province

Guilan

Postal code

54839 -41446

Phone

+98 13 3336 9224

Email

maryam_atari4950@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

There are no plans to share and publish it, yet

When the data will become available and for how long

The beginning of the access period is 6 months after the publication of the study results.

To whom data/document is available

All interested in study

Under which criteria data/document could be used

All interested in study

From where data/document is obtainable

by Email

What processes are involved for a request to access data/document

Not yet planned for it.

Comments